230617-67-1

Basic information

• Product Name: 2-chloro-5-(piperidin-1-ylmethyl)pyridine
• Synonyms: 2-chloro-5-(piperidin-1-ylmethyl)pyridine;2-CHLORO-5-(1-PIPERIDINYLMETHYL)-PYRIDINE;2-chloro-5-(1-piperidinylmethyl)pyridine(SALTDATA: FREE)
• CAS NO: 230617-67-1
• Molecular Formula: C11H15ClN2
• Molecular Weight: 210.706
• Mol File: 230617-67-1.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-chloro-5-(piperidin-1-ylmethyl)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-5-(piperidin-1-ylmethyl)pyridine(230617-67-1)
• EPA Substance Registry System: 2-chloro-5-(piperidin-1-ylmethyl)pyridine(230617-67-1)

Safety Data

• Hazardous Substances Data: 230617-67-1(Hazardous Substances Data)

Upstream product

• 110-89-4 piperidine 
• 70258-18-3 2-chloro-5-(chloromethyl)pyridine 

Relevant articles and documents

(HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS

The present invention relates to (hetero)aryl compounds of general formula (I) wherein the groups and radicals A, B, Q, W, X, Y, Z, R1, R2, R4a, R4b, R5a, R5b, have the meanings given in cl

Substituted pyridines as modulators of the mammalian neuronal nicotinic acetylcholine receptor

Novel compounds are provided that modulate the neuronal nicotinic acetylcholine receptor (nAChR), particularly the mammalian nAChR (m-nAChR). The compounds are substituted pyridine derivatives such as analogs of 1-[(6-chloro-3-pyridinyl)methyl]-2-imidazolidine and 1-[(6-chloro-3-pyridinyl)methyl]-2-iminothiazole. Methods of using the novel m-nAChR modulators are also provided, including methods of using the compounds as m-nAChR probes and as therapeutic agents to treat mammalian individuals suffering from conditions, disorders or diseases that are responsive to administration of an m-nAChR modulator. The compounds are useful in treating (1) CNS disorders such as Alzheimer's disease, AIDS-associated dementia, Tourette's Syndrome, attention deficit disorder, and attention deficit disorder, (2) inflammation and inflammatory diseases, (3) conditions caused by or associated with smooth muscle contractions, and (4) withdrawal symptoms associated with cessation of chemical substance abuse. The compounds are also useful as non-opiate analgesics, to treat mild, moderate or severe pain. Pharmaceutical formulations containing an m-nAChR modulator of the invention are provided as well.